Novo Nordisk to showcase new data across its hemophilia portfolio at the ISTH Congress 2026, featuring investigational denecimig
PR Newswire
PLAINSBORO, N.J. and BAGSVÆRD, Denmark, June 26, 2026
FRONTIER4 data on investigational denecimig: Exploring efficacy and safety across dosing frequencies for pediatric, adolescent, and adult hemophilia A patients, with or without inhibitorsExplorer10 data on concizumab (Alhemo®): Details presented for pediatric hemophilia A or B patients (up to 11 years old), with inhibitorsData underscores the breadth of Novo Nordisk's hemophilia portfolio, building on Novo Nordisk's legacy across rare blood disordersPLAINSBORO, N.J. and BAGSVÆRD, Denmark, June 26, 2026 /PRNewswire/ -- Novo Nordisk today announced that new data will be presented at the upcoming International Society on Thrombosis and Haemostasis (ISTH) Congress, July 11-15 in Paris, France. The broad range of oral and poster presentations spans the Novo Nordisk hemophilia portfolio and is highlighted by multiple analyses of the phase 3 FRONTIER4 study evaluating the long-term efficacy and safety of investigational denecimig (Mim8) across a range of age groups and dosing frequencies, including once-monthly, once-every-two-weeks, and once-weekly prophylaxis. Additional insights from the portfolio will span clinical and real-world treatment data as well as patient-reported outcomes.
